VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IWWM-11 2022 | Updates on the use of zanubrutinib in WM patients intolerant to ibrutinib or acalabrutinib

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly discusses the safety and efficacy of zanubrutinib in patients with Waldenström’s macroglobulinemia (WM) who are intolerant to ibrutinib or acalabrutinib. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter